MorphoSys Extends Alliance With Schering-Plough

Anonymous User | Login

Published: 16-Jun-2009

Schering-Plough to have continued access to HuCAL GOLD

Schering-Plough has triggered its pre-existing option to extend the current collaboration with MorphoSys for another year.

Schering-Plough will have continued access to MorphoSys's proprietary antibody HuCAL GOLD, and contains options for therapeutic licenses.

For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to get license fees and milestone payments relating to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement.

Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform.

Simon Moroney, CEO of MorphoSys, said: We are pleased with Schering-Plough's decision to extend the current collaboration.

Roche Selects Fifth Biologic Target Under Collaboration Agreement With Halozyme

Roche to pay Halozyme $4.25 million for global rights for the application of its hyaluronidase enzyme, rHuPH20 ...

Abbott Initiates Spirit Prime Trial

Results to be used to support regulatory filing for Xience Prime ...

GSK's Syncria Improves Glucose Control, Reduces Weight

Syncria (Albiglutide) to reduce blood sugar in the treatment of type2 diabetes. ...

Orexigen Signs Licensing Agreement With GSK

To submit NDA in the first half of 2010 ...

Concert Pharmaceuticals, GlaxoSmithKline Collaborate For Deuterium-containing Medicines

Concert to receive $35 million in upfront payments, and will provide GSK with deuterium-modified versions of three GSK pipeline compounds for development. ...

FDA Approves GlaxoSmithKline' Lamictal XR For Epilepsy Treatment

GlaxoSmithKline has announced that the US Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine) Extended-Release tablets as once-a-day add-on therapy ...

Sanofi-Aventis To Purchase Diabel Manufacturing Facility In Frankfurt

Scope of acquisition includes buildings, equipment, machinery and some existing contracts ...

Eli Lilly Announces New Drug Discovery Initiative

Lilly' Phenotypic Drug Discovery Initiative to use indigeneously developed disease-state assays and secure web portal ...

Pfizer' Reveals Results For Four Lung Cancer Trials

Pfizer has announced positive results from four studies highlighting clinical data with targeted treatment approaches in patients with non-small cell lung cancer. The ong ...

Schering Plough Wins Marketing Approval For Sycrest

Sycrest tablets to treat schizophrenia and manic episodes associated with bipolar I disorder. ...

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://www.pharmaceutical-business-review.com/news/morphosys_extends_alliance_with_scheringplough_090616/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Almac

Drug Development Solutions ...

STARLIMS

Benefits for Life Science Labs ...

Parenteral Drug Association (PDA)

Pharmaceutical Information and Education Services ...

Burkert Fluid Control Systems

Fluid and Gas Control Systems ...

IMCOR

LIMS and Laboratory Informatics Consultancy ...

Umicore Precious Metals Chemistry

Chemicals and Catalysts for Industrial Applications ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (Takeda) is a global pharmaceutical company mainl ...

Roche Holding Ltd

Roche Holding Ltd (Roche) is one of the major research based healthcare group in the wo ...

Pfizer Inc.

Pfizer Inc. (Pfizer) is a global research based pharmaceutical company principally focu ...

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Schering-Plough Corporation

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750